Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer.

J Clin Invest · 2025 · PMC12208538 · PMID 40392598

Europe PMC DOI

hedged sentence

0.4000

closest p · 8.0× alpha

0.4000

boldest claim

The sentences

showed a trendP = 0.4not close (p > 0.1)

Patients with p-RPA2-high HGSCs showed a trend toward increased PFS (17.1 vs. 9.9 months, hazard ratio 0.7, 95% CI 0.3–1.7, P = 0.4) and OS (47.1 vs. 32.7 months, hazard ratio 0.60, 95% CI 0.24–1.51, P = 0.3) compared with those with p-RPA2-low HGSCs ( Figure 1C and Supplemental Figure 4 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.